Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying adult patients who have had an acute ischemic stroke caused by blockage in medium-sized brain blood vessels. This trial aims to evaluate the effectiveness and safety of tenecteplase compared to standard medical care in patients treated within 4.5 to 24 hours after stroke symptoms begin. The study focuses on a specific group with confirmed medium vessel occlusions and uses imaging methods to select participants based on brain blood flow and damage. Participants will be randomly assigned to receive either a single intravenous dose of tenecteplase 0.25 mg per kilogram, up to 25 mg or standard medical treatment, which may include aspirin andor clopidogrel, following national stroke care guidelines. Treatments will be given between 4.5 and 24 hours after the patient was last seen well. The trial is controlled, randomized, and open-label with blinded evaluation of outcomes. During the study, participants will be monitored through clinical assessments including the National Institutes of Health Stroke Scale and the modified Rankin scale to measure disability at 90 days. Imaging tests such as CT or MRI perfusion scans will be used to evaluate brain blood flow and damage. Researchers will track neurological improvement, adverse events, bleeding events, and quality of life up to one year after treatment. The main outcome is the proportion of patients achieving minimal disability at 90 days post-treatment.
Actively Recruiting
Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.
Actively Recruiting
Researchers are evaluating the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke who are undergoing endovascular thrombectomy. This phase 2, multicenter, randomized, double-blind, placebo-controlled study aims to understand how this drug affects patients treated within 24 hours of stroke onset. The trial involves adult participants aged 18 to 80 years with specific types of large-vessel occlusion in the brain. Participants will be randomly assigned to receive either anisodine hydrobromide or a placebo, both given alongside standard endovascular thrombectomy care. The drug is administered as an intravenous infusion of 2 mg diluted in saline twice daily for a total of 14 doses. The placebo group receives an equivalent volume of saline infusion on the same schedule. Both groups will be monitored during follow-up to assess treatment effects and safety. During the study, participants will undergo regular evaluations including neurological assessments using NIH Stroke Scale and modified Rankin Scale scores, along with brain imaging to measure cerebral infarct volume on day 8. Additional outcome measures at 90 days include functional independence and quality of life assessments. Safety is closely monitored, and participants are followed until study completion in March 2027.